171 related articles for article (PubMed ID: 8500224)
61. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
62. Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies.
Najajreh Y; Khazanov E; Jawbry S; Ardeli-Tzaraf Y; Perez JM; Kasparkova J; Brabec V; Barenholz Y; Gibson D
J Med Chem; 2006 Jul; 49(15):4665-73. PubMed ID: 16854072
[TBL] [Abstract][Full Text] [Related]
63. Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes.
Khokhar AR; al-Baker S; Perez-Soler R
Anticancer Drugs; 1992 Apr; 3(2):95-100. PubMed ID: 1525398
[TBL] [Abstract][Full Text] [Related]
64. Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-a]pyrimidine derivatives: structural characterization and mechanism of the suppression of tumor cell growth.
Łakomska I; Hoffmann K; Wojtczak A; Sitkowski J; Maj E; Wietrzyk J
J Inorg Biochem; 2014 Dec; 141():188-197. PubMed ID: 25277461
[TBL] [Abstract][Full Text] [Related]
65. In vitro histoculture drug response assay and in vivo blood chemistry of a novel Pt(IV) compound, K104.
Kwon YE; Park JY; Kim WK
Anticancer Res; 2007; 27(1A):321-6. PubMed ID: 17352249
[TBL] [Abstract][Full Text] [Related]
66. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
67. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
[TBL] [Abstract][Full Text] [Related]
68. [Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1253-61. PubMed ID: 22024542
[TBL] [Abstract][Full Text] [Related]
69. [The prospect for cisplatin analogs from the experimental standpoint].
Tashiro T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
[TBL] [Abstract][Full Text] [Related]
70. cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents.
Hollis LS; Miller AV; Amundsen AR; Schurig JE; Stern EW
J Med Chem; 1990 Jan; 33(1):105-11. PubMed ID: 2296007
[TBL] [Abstract][Full Text] [Related]
71. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
73. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
74. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
75. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin.
To KK; Ho YP; Au-Yeung SC
Cancer Lett; 2005 Jun; 223(2):227-37. PubMed ID: 15896457
[TBL] [Abstract][Full Text] [Related]
76. Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin.
Yoshida M; Khokhar AR; Kido Y; Ali-Osman F; Siddik ZH
Biochem Pharmacol; 1994 Aug; 48(4):793-9. PubMed ID: 8080453
[TBL] [Abstract][Full Text] [Related]
77. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
78. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
79. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
[TBL] [Abstract][Full Text] [Related]
80. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
